EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals Inc.
WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
10,95 €
-0,68 %
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $46.00 to $38.00. They now have an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $35.00 to $32.00. They now have an "overweight" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $29.00. They now have an "overweight" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Chardan Capital from $28.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $30.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $38.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $33.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Chardan Capital from $33.00 to $27.00. They now have a "buy" rating on the stock.
Ratings data for EYPT provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in adidas AG ADR diskutieren